InStent EndoCoil biliary stent is awaiting 510(k) clearance -- IPO.
This article was originally published in The Gray Sheet
INSTENT ENDOCOIL STENT FOR MALIGNANT BILIARY STRICTURES due to pancreatic cancer is awaiting 510(k) clearance by FDA, the firm notes in a registration statement filed with the Securities and Exchange Commission for an initial public offering. The company "has responded to requests from FDA for additional information" on the 510(k) and "is currently awaiting FDA action," the filing states.
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.